Common Technical Document (CTD) format: adopted guidelines

CHMP/EWP/252/03
Guideline on clinical investigation of medicinal products intended for the treatment of neuropathic pain. Effective: 1 June 2005

CPMP/BWP/5180/03
Guideline on assessing the risk for virus transmission - new chapter 6 of the note for guidance on plasma - derived medicinal products (CPMP/ BWP/269/95). Effective: 20 May 2005

CPMP/EWP/788/01
Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Migraine. Effective: 20 May 2005

CPMP/EWP/2863/99
Points to Consider on Adjustment for Baseline Covariates. Effective: 20 May 2005

CPMP/EWP/3020/03
Note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders. Effective: 20 May 2005

CPMP/BWP/CPMP/5136/03
Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to VCJD risk. Effective: 12 May 2005

EMEA/CPMP/3097/02
Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Effective: 12 May 2005

CPMP/EWP/612/00
Note for Guidance on Clinical Investigation of Medicinal Products for Treatment of Nociceptive Pain. Effective: 12 May 2005

EMEA/CPMP/BWP/3207/00, rev 1
Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. Effective: 2 May 2005

CPMP/SWP/2599/02, rev 1
Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. Effective: 2 May 2005

EMEA/CPMP/BWP/3794/03
Guideline on the Scientific Data Requirements for a Plasma Master File (PMF). Effective: 18 February 2005

Available from: http://www.emea.eu.int/whatsnewp.htm